Click Here to return To Results

 

Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, NEJM 333:1581-1587, 12,1995., 1995 See this aricle in Pubmed Article Abstract In part 1,there was no significant difference between the group given t-PA and that given placebo in the percentages of patients with neurologic improvement at 24 hours,although a benefit was observed for the t-PA group at three months for all four outcome measures.In part 2,the long-term clinical benefit of t-PA predicted by the results of part 1 was confirmed (global odds ratio for a favorable outcome,1.7;95 percent confidence interval,1.2 to 2.8).As compared with patients given placebo,patients treated with t-PA were at least 30 percent more likely to have minimal or no disability at three months on the assessment scales.Symptomatic intracerebral hemorrhage within 36 hours after the onset of stroke occurred in 6.4 percent of patients given t-PA but only 0.6 percent of patients given placebo(P<0.001).Mortality at three months was 17 percent in the t-PA group and 21 percent in the placebo group(P=0.30).Despite an increased incidence of symptomatic intracerebral hemorrhage,treatment with intravenous t-PA within three hours of the onset of ischemic stroke improved clinical outcome at three months.

Related Tags

(click to filter results - removes previous filter) cerebral ischemia cerebrovascular accident cerebrovascular accident,acute management of cerebrovascular accident,thrombolytic agents in treatment fibrinolytic agents fibrinolytic agents,complications iatrogenic neurologic disorders intracerebral hemorrhage tissue plasminogen activator,intravenous treatment of neurologic disorder

Click Here to return To Results